Brief: Q32 Bio Inc To Discontinue Renal Basket Trial For Adx-097 To Conserve Resources
10/02/2025 21:38
Q32 Bio Inc QTTB.O :
* Q32 BIO INC: TO DISCONTINUE RENAL BASKET TRIAL FOR ADX-097
TO
CONSERVE RESOURCES
* Q32 BIO INC: EVALUATE STRATEGIC OPTIONS FOR ITS
TISSUE-TARGETED
COMPLEMENT INHIBITOR PLATFORM
* Q32 BIO INC: CASH RUNWAY EXPECTED TO EXTEND TO 2H'26
* Q32 BIO INC: INITIATING OPEN-LABEL EXTENSION FROM
SIGNAL-AA
PART A IN 1H'25
* Q32 BIO INC: SIGNAL-AA PART B REMAINS ON TRACK FOR
INITIATION OF
DOSING IN 1H'25, WITH TOPLINE DATA EXPECTED IN 1H'26
Source text: ID:nPn11yPfKa
Further company coverage: QTTB.O
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview